key: cord-0715684-uo6e70to authors: Yoon, Chang Ho; Choi, Hyuk Jin; Kim, Mee Kum title: Corneal xenotransplantation: Where are we standing? date: 2020-08-02 journal: Prog Retin Eye Res DOI: 10.1016/j.preteyeres.2020.100876 sha: eaf3cdb0470945492abbd750d0cbba52ee9900d4 doc_id: 715684 cord_uid: uo6e70to The search for alternatives to allotransplants is driven by the shortage of corneal donors and is demanding because of the limitations of the alternatives. Indeed, current progress in genetically engineered (GE) pigs, the introduction of gene-editing technology by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and advanced immunosuppressants have made xenotransplantation a possible option for a human trial. Porcine corneal xenotransplantation is considered applicable because the eye is regarded as an immune-privileged site. Furthermore, recent non-human primate studies have shown long-term survival of porcine xenotransplants in keratoplasty. Herein, corneal immune privilege is briefly introduced, and xenogeneic reactions are compared with allogeneic reactions in corneal transplantation. This review describes the current knowledge on special issues of xenotransplantation, xenogeneic rejection mechanisms, current immunosuppressive regimens of corneal xenotransplantation, preclinical efficacy and safety data of corneal xenotransplantation, and updates of the regulatory framework to conduct a clinical trial on corneal xenotransplantation. We also discuss barriers that might prevent xenotransplantation from becoming common practice, such as ethical dilemmas, public concerns on xenotransplantation, and the possible risk of xenozoonosis. Given that the legal definition of decellularized porcine cornea (DPC) lies somewhere between a medical device and a xenotransplant, the preclinical efficacy and clinical trial data using DPC are included. The review finally provides perspectives on the current standpoint of corneal xenotransplantation in the fields of regenerative medicine. Porcine corneal xenotransplantation is considered applicable because the eye is regarded as an immune-privileged site. Furthermore, recent non-human primate studies have shown long-term survival of porcine xenotransplants in keratoplasty. Herein, corneal immune privilege is briefly introduced, and xenogeneic reactions are compared with allogeneic reactions in corneal transplantation. This review describes the current knowledge on special issues of xenotransplantation, xenogeneic rejection mechanisms, current immunosuppressive regimens of corneal xenotransplantation, preclinical efficacy and safety data of corneal xenotransplantation, and updates of the regulatory framework to conduct a clinical trial on corneal xenotransplantation. We also discuss barriers that might prevent xenotransplantation from becoming common practice, such as ethical dilemmas, public concerns on xenotransplantation, and the possible risk of xenozoonosis. Given that the legal definition of decellularized porcine cornea (DPC) lies somewhere between a medical device and a xenotransplant, the preclinical efficacy and clinical trial data using DPC are included. 1 potential of the endothelial cells in the porcine cornea should be similar to those of humans. 2 Indeed, the proliferative potential of porcine corneal endothelial cells is comparable to that of 3 humans, irrespective of WT or GT-KO pigs (Fujita et al., 2013; Kim et al., 2016) . Furthermore, porcine corneal endothelial cell density (CED) decreases with age, similarly to 5 humans (Table 6 ) Snellingen et al., 2001) and the age-dependent 6 decrease of CED in GE pigs is higher than that in WT pigs (Table 6 ) (Kim and Hara, 2015) . Given that more than 2200/mm 2 of the CED is preferred for a donor graft, the pig's age may 8 be limited in accordance with the CED. A previous study reported that the age of WT pigs 9 may be limited to 72 months old or younger for suitable grafts (CED ≥2200 cells/mm 2 ) or 48 10 months old or younger for qualified grafts (CED ≥2500 cells/mm 2 ). The age limitation of GE 11 pigs may be different from that of WT pigs. Indeed, preservation time-dependent decrease of 12 CED is comparable to that in humans as a suitable graft, regardless of WT or GT-KO pigs 13 Yoon et al., 2020) . In summary, the mechanical and biophysical properties 14 of porcine cornea are comparable to those of humans when the selected donor is of an 15 appropriate age. 16 17 18 To understand the different xenogeneic rejections between the vascular organ and the 20 cornea, we will briefly mention rejection responses in cardiac or renal pig-to-NHP 21 xenotransplantation ( Fig. 3A ) Sprangers et al., 2008) ; (1) is mediated mainly by CD4 + T cells and macrophages. However, the detailed mechanism of 1 chronic rejection is not well known because acute humoral and cellular rejection has not 2 been overcome in cardiac and renal xenotransplantation so far. To acknowledge the differences between xenogeneic and allogeneic responses in 4 keratoplasty, allogeneic rejection is described hereafter. Although the eye is an immune-5 privileged site, allogeneic rejection still occurs due to the breach of immune-privilege ( Fig. 6 3B). Allogeneic rejection is mediated primarily by CD4 + T cells (He et al., 1991; Qian and 7 Dana, 2001) . It has been debated whether CD8 + T cells mediate allogeneic rejection 8 (Boisgerault et al., 2001; Niederkorn et al., 2006a, b; Qian and Dana, 2001) . In early studies, CD8 + T cells do not contribute to allogeneic rejection (Boisgerault et al., 2001; Qian and 10 , however recent studies show CD8 + T cell-mediated rejection despite slow 11 responses (Niederkorn et al., 2006a, b) . Under high-risk circumstances, allotransplants can 12 be rejected by stimulating complement-dependent cytolytic Abs (Hargrave et al., 2000; 13 Niederkorn, 2007) . It has been also reported that NK cells have a role in corneal allogeneic 14 rejection (Claerhout et al., 2004; Schwartzkopff et al., 2010) . The immunological barriers in corneal xenotransplantation is less than in solid organ 18 xenotransplantation, however it exceeds the barriers in corneal allotransplantation (Larkin 19 and Williams, 1995) . Early studies employ small animal models (i.e. rodent) to investigate 20 the rejection mechanism, or medium to large animals (i.e. rabbit, cat, pig, NHP) to evaluate 21 the efficacy as a preclinical trial with various donors (fish, rabbit, chicken, dog, pig, cow, sheep, NHP, human) (Hara and Cooper, 2010; Larkin and Williams, 1995; Ross et al., 1993) . Herein, xenogeneic rejection mechanisms are shown in early studies with variant donors 24 except pig donors ( Table 7) . The graft survival and xenogeneic rejection mechanism are 25 affected depending on phylogenetic discordance, size of the donor, surgical and post-26 operative trauma, and different animal models (host immune system) (Hara and Cooper, 27 2010), In the rat models, Ross et al (Ross et al., 1993; Ross et al., 1994) and Larkin et el (Larkin 1 and Williams, 1995) reported that there was 1) no hyperacute rejection, 2) infiltration of T cell, 2 neutrophil and macrophage, and deposition of Ig G and Ig M in the graft, and 3) production 3 of xenoreactive Ig M and Ig G post-transplantation or preformed xenoreactive Abs in the 4 serum. It has been also reported that sensitization to xenoantigen accelerated corneal 5 xenogeneic rejection (Ross et al., 1993) and similar rejection time was detected in athymic 6 rats (3 days) compared to that in euthymic rats (3 days) , suggesting an important role of the 7 innate immune system (Larkin and Williams, 1995) . Infiltration of eosinophils were also 8 found in some rat model (Larkin and Williams, 1995) . Taken together, acute humoral 9 response with later cell-mediated response is the critical feature differentiating xenogeneic 10 from allogeneic rejection. In mice models, graft survival seems to be relatively longer than that in the rat model. Most mice studies support the importance of CD4 + T cell- Pindjakova et 13 al., 2005; Tanaka et al., 2000) or T cell- (Sedlakova et al., 2005; Yamagami et al., 1997) 14 mediated xenogeneic rejection. Involvement of complement (Tanaka et al., 2000) or indirect 15 pathway of T-cell activation through the recipient's MHCII + antigen-presenting cells in 16 xenogeneic rejection (Tanaka et al., 2001) has been also reported. Although Tanaka et al 17 demonstrated no role of B cells using µ KO mice (Tanaka et al., 2000) , other three reports 18 indicate the involvement of humoral response in xenogeneic rejection 19 Sedlakova et al., 2005; Yamagami et al., 1997) . Meanwhile, mice studies did not indicate an 20 involvement of CD8 + T cells in xenogeneic rejection (Pindjakova et al., 2005; , on the contrary, a rat study presented CD8 + T cells in xenotransplants (Larkin and 22 Williams, 1995) . Additionally, corneal xenotransplants in CD4 + T cell-depleted mice are 23 susceptible to rejection by interferon (IFN)γ secreting CD8 + T cells not by cytotoxic CD8 + T 24 cells (Higuchi and Streilein, 2003) . In rabbit or pig studies, eosinophil, lymphocytes, neutrophils, or macrophages were 26 observed in the grafts, and increased CD4 + T cells and preformed Abs were observed in the 27 blood (Babel and Bourquin, 1952; Faber et al., 2009) . Currently, through small to medium 28 animal studies, evidences have emerged that both cellular and humoral immune responses 1 are involved in corneal xenogeneic rejection (Hara and Cooper, 2010) . Taken together, the 2 effect of the each immune cell or humoral factors on xenogeneic rejection are suggested in 3 the following order; CD4 + T cells >>>> macrophages >>> Abs, complement >> neutrophils, 4 eosinophils > CT8 + T cells (Table 7 ) (Hara and Cooper, 2010) . It has been reported that 5 NK/NK-T cells are not involved in corneal xenograft rejection (Tanaka et al., 2000) . Corneal pig-to-NHP xenotransplants survive longer (>933 days) than orthotopic cardiac 9 (>195 days) or renal (310 days) pig-to-NHP xenotransplants (Choi et al., 2015; Cooper et al., 10 2014; Langin et al., 2018; Wijkstrom et al., 2017) , suggesting less immunological barriers. HAR is not observed in porcine corneal xenotransplants unlike solid organs (Hara and 12 Cooper, 2010) . Given that both αGal and non-αGal (e.g. N-glycolylneuraminic acid (NeuGc)) 13 are expressed in porcine corneal cells, acute humoral rejection (i.e. DXR) still occurs (Cohen 14 et al., 2014; Kim et al., 2009; Lee et al., 2007) . Although αGal-related immune response 15 does not occur in pig-to-rodents or pig-to-rabbits due to the expression of αGal epitopes in 16 host animals, huge disparities of the hierarchical discordance and size between pig and 17 rodents/rabbits still cause the short survivals. Xenogeneic rejection mechanism in orthotopic 18 porcine corneal transplantation using small or medium animals are shown in Table 8 . In the rat models, 1) infiltration of T cells and macrophages are evident in the graft, 2) 20 neutrophils and monocytes were found, 3) CD8 + T cells were found more than CD4 + T cells 21 unlike in mouse model, and 4) NK cells were rarely found (Lee et al., 2008; Lee et al., 2010; 22 Oh et al., 2009b) . Humoral response had not been investigated in a pig-to-rat corneal 23 transplantation. Furthermore, the systemic administration of steroid, cyclosporin and 24 mycophenolate mofetil (MMF) or the topical application of allogenic rat mesenchymal stem 25 cells (MSCs) did not prolong graft survivals (Lee et al., 2008; Oh et al., 2009b) . In mice models, the median survival time (MST) of the grafts was significantly prolonged in 27 nude (T cell-defective), severe combined immunodeficiency (SCID; T and B cell-defective), 28 13 or NOD/SCID/γc null (NOG; T, B, and NK cell-defective) mice compared to WT mice (Oh et al., 1 2009a). MST was not different among the nude, SCID, and NOG mice, suggesting that T 2 cells are important for the rejection compared with B or NK cells (Oh et al., 2009a) . The MST 3 significantly increased in both WT and SCID mice when complement depleted by cobra 4 venom factor (Oh et al., 2010) . Histology also showed that 1) infiltration of CD4 + T cells and 5 macrophages, and deposition of Ig M and Ig G are evident, 2) neutrophils and eosinophils 6 were found in early period and monocytes were infiltrated later, 3) CD8 + T cells and NK cells 7 were rarely found (Choi et al., 2011a; Oh et al., 2009a; Oh et al., 2010) . Furthermore, a pig-8 to-GT-KO mouse corneal xenotransplantation study showed that a gradual increase of IgG 9 αGal Ab in the plasma and deposition of anti-αGal Ig G and Ig M in the grafts (Choi et al., 10 2011a) . In an in vitro study, the absence of αGal or NeuGc on corneal endothelial cells 11 reduced human Ab binding . Hence, αGal or non-αGal might have a role in 12 corneal xenotransplantation. In pig-to-rabbit corneal xenotransplantation, T cells, monocytes, and eosinophils are found 14 (Oh et al., 2009c; Oh et al., 2009d; Oh et al., 2008) and lamellar grafts survived longer than 15 full thickness grafts (Oh et al., 2009c) . Based on histological analysis in rejected grafts of 16 NHPs (Table 9) , CD4 + and CD8 + T cells, macrophages, B cells and deposition of Ig G and 17 complement are observed, and neutrophils and eosinophils are sometimes found. Moreover, 18 aqueous humor activated complement and CD8 + IFNγ + cells in the blood have been reported 19 to be a predictive biomarker of xenogeneic rejection in NHPs (Yoon et al., 2019) . Hence, the 20 critical role of the complement in xenogeneic rejection is presumably related with the fact 21 that the porcine equivalent complement-regulatory protein is less capable of providing 22 protection from the activation of the human complement; this probably due to relatively 23 species-specific complementary modulatory proteins (Larkin and Williams, 1995; 24 2019). Involvement of CD8 + IFNγ + cells in NHPs corresponds with that of a previous SCID 25 mouse study reconstituted with CD4 + T cell-depleted splenocytes (Higuchi and Streilein, 26 2003) . Increased donor specific Ig G and anti-non-αGaI Ig G are consistently observed in 27 most NHPs with rejected grafts, while anti-αGal Ig M / Ig G increased in rejected WT grafts 28 14 (Table 9 ). 1 Therefore, xenogeneic rejection mechanisms in porcine corneal xenotransplantation are 2 summarized as follows ( Fig. 3C ): (1) HAR is not seen in all animal models, (2) acute and 3 chronic rejections are evident through CD4 + T cell-mediated cellular, humoral, and 4 complement-mediated innate responses, (3) involvement of CD8 + T cell is different 5 depending on the animal models, and CD8 + T cell-associated rejection is evident in NHP 6 model, and (4) NK cell-associated rejection is not seen in all the animal models. A few studies on the immunogenicity of MHC in xenogeneic rejection have been reported. (Byrne, 2018; Mulder et al., 2010) . Furthermore, an evidence indicates that porcine cells present SLA antigens directly to human T cells 17 (Murray et al., 1994) , suggesting that MHC antigen-mediated T cell response may have a 18 role in xenotransplantation. Additionally, CIITA-DN transgenic pigs that reduce SLA class II 19 expression also inhibit human anti-pig T cell responses . Moreover, SLA I 20 was expressed in both pig corneal and aortic endothelial cells with in vitro human CD4 + T 21 cell responses against them (Hara et al., 2011) . Therefore, it is possible that SLA mediated T cell responses or recipient's MHC antibody mediated cross-responses in corneal 23 xenogeneic rejection. The principal goal of immunomodulating agent administration is to balance the benefit of 27 rejection prevention and the risk of over-immunosuppression. To find the optimal 28 combinations to prevent xenogeneic rejection, almost all immunosuppressants currently 1 applied to allotransplantation, along with various biologic agents under investigation, have 2 been tested in pig-to-NHP transplantation models, which are considered the optimal animal 3 models to justify initiating a clinical trial (Hering et al., 2016; Kim et al., 2014) . Table 10 4 shows various kinds of immunosuppressants and their mechanism of action in the immune 5 system. Table 10 also includes effective drugs that enabled long-term survival of the porcine 6 heart, kidney, islet and corneal grafts in NHP recipients for more than 6 months. Although 7 targeted genetic manipulation of the donor pig has allowed to significantly reduce 8 immunosuppression, potent systemic immunosuppressive strategies are still needed to 9 overcome antigenic differences between species. Conversely, common protocols used for 10 induction and maintenance therapy in current solid organ allotransplantation including heart, 11 liver, lung, kidney and pancreas (Chang et al., 2014; Costa et al., 2017; Dhanasekaran, 12 2017; Kimelman and Brandacher, 2013; Lim et al., 2017) are less effective in 13 xenotransplantation. 14 15 Given the huge antigenic difference between pig and humans, the clinical application of a 17 porcine corneal graft may need specific management of high-risk corneal allotransplantation. The following management is suggested for high-risk corneal allotransplantation. As preoperative management, a useful approach is to reduce the host corneal 20 neovascularization with corticosteroids (CSs) (Kim et al., 2013a) or anti-VEGF Ab (Bock et 21 al., 2013; Fasciani et al., 2015; Vassileva and Hergeldzhieva, 2009 ). In addition to CS, topical cyclosporine A (CsA) 2% (Belin et al., 1989; Inoue et al., 2000) or tacrolimus 0.03% 23 (Dhaliwal et al., 2008; Magalhaes et al., 2013) are reported to be effective in high-risk 24 keratoplasty as a selective T cell inhibitor. Regarding a systemic immunosuppressive 25 regimen, CSs represents the key medication Di Zazzo et al., 2017; Hos 26 et al., 2019) and CsA has long been used to prevent rejection in high-risk corneal 27 allotransplantation. However, there has been no consensus on its efficacy (Hill, 1994; 28 Shimazaki et al., 2011) . In summary, tacrolimus, MMF, and rapamycin have been reported to 1 be administered in high-risk recipients (Birnbaum et al., 2006; Chatel and Larkin, 2010; 2 Joseph et al., 2007 Basiliximab is a chimeric monoclonal antibody (mAb), which competitively inhibits the alpha 14 subunit of the IL-2 receptor (CD25) (Rodrigues et al., 2009) ; it inhibits T-cell proliferation but 15 does not cause depletion and is used in combination with other immunosuppressants with 16 no increase in adverse effects (Henry and Rajab, 2002) . Rituximab is also a chimeric mAb 17 against the protein CD20 primarily on B cells. Both basiliximab and rituximab have been 18 used for corneal pig-to-NHP studies and showed long-term survival of grafts (Kim et al., 19 2018a; Yoon et al., 2020) . Intravenous immunoglobulin (IVIG) products are derived from 20 pooled human plasma and suppress APC activity, Ab production, and complement activation. IVIG has emerged as an important component of desensitization protocols and for the 22 treatment of antibody-mediated rejection (AMR) and pig-to-NHP corneal xenotransplantation 23 (Choi et al., 2015; Jordan et al., 2011 (Cardona et al., 2006; Thompson et al., 2011) . It can increase the risk of 2 posttransplant lymphoproliferative disorder (PTLD) in Epstein-Barr virus (EBV)-seronegative 3 recipients (Vincenti et al., 2005) . Anti-CD154 Ab is the one of the main therapy used in cardiac, renal, or corneal pig-to-NHP 5 transplantation (Choi et al., 2015; Langin et al., 2018; Wijkstrom et al., 2017) . Based on the 6 preclinical efficacy of anti-CD154 treatment, a clinical trial was initiated using a humanized 7 anti-CD154 mAb (ruplizumab/BG9588) in kidney transplantation (Kirk et al., 2001) . However, 8 the development of this drug was discontinued because of concerns related to 9 thromboembolic complications (Kawai et al., 2000; Koyama et al., 2004) . Anti-CD154 mAb 10 can directly activate platelets since CD154 is expressed on the platelet surface (Xu et al., 11 2006) . At least three anti-CD154 Abs (letolizumab/BMS-986004, dapirolizumab 12 pegol/CDP7657, and VIB4920) have been developed to minimize thromboembolic 13 complications and are undergoing human clinical trial for autoimmune diseases (Schroder et 14 al., 2019) , which are expected to be applied in the xenotransplantation field. CD40 became an alternative therapeutic target to avoid thromboembolic complications in 16 cardiac and corneal pig-to-NHP transplantation (Kim et al., 2018a; Langin et al., 2018) . Bleselumab/ASKP1240 is a fully human IgG4 anti-CD40 mAb, and a recent phase II clinical 18 trial for kidney transplantation demonstrated noninferiority to tacrolimus and MMF-based 19 standard care (Harland et al., 2020) . CFZ533 is an anti-CD40 mAb with a modified Fc 20 domain (Ristov et al., 2018) MSCs are studying the minimization of immunosuppression in renal and liver transplantation 10 (Reinders et al., 2018) . Mixed chimerism is defined as a state where donor and recipient hematopoietic cells 12 coexist at levels sufficient to be detected by standard techniques. Mixed chimerism has been 13 used for renal and corneal pig-to-NHP studies (Jie et al., 2013; Sachs, 2018 Although parts of pig-to-NHP studies showed CS-based regimens prolonged the survival of 22 grafts, CS-only immunosuppression does not guarantee the long-term survival of grafts even 23 in lamellar keratoplasty (LKP) models (Choi et al., 2011b; Vabres et al., 2014; Zhiqiang et al., 24 2007) . The introduction of GE pigs or mixed chimerism did not show long-term survival of 25 xenotransplants (Dong et al., 2017; Jie et al., 2013; Vabres et al., 2014) . In contrast, both 26 anti-CD154 mAb-and anti-CD40 Ab-based immunosuppression significantly prolonged the 27 survival of WT corneal xenotransplants (Choi et al., 2015; Kim et al., 2018a; 28 1 that a combination of commercially available drugs, including rituximab and tacrolimus, also 2 demonstrated long-term survival of both WT and GT-KO full-thickness xenotransplants (Choi 3 et al., 2018; Kim et al., 2018a; Yoon et al., 2020) . Induction therapy and preventions of AMR 4 seem to be crucial, and to date, induction using CS, basiliximab, IVIG, and rituximab and 5 maintenance with tacrolimus and rituximab are a feasible option for human clinical trials 6 based on pig-to-NHP corneal transplantation data (Choi et al., 2019b; Kim et al., 2018a) . Since a recent pig-to-NHP endothelial keratoplasty (EK) study showed efficacy under 8 subconjunctival injection of CSs , this implies that a regional CSs might be 9 an option for patients with compromised endothelial cells. Regarding general health status, NHP recipients with porcine corneal transplants 11 maintained good appetite and physical activity during the long-term period of 12 immunosuppression using CSs-, costimulatory blockade agents-, and 13 rituximab/tacrolimus/basiliximab-based regimens, although costimulatory blockade agents 14 and rituximab/tacrolimus/basiliximab induced early weight loss (Choi et al., 2015; Choi et al., 15 2018; Kim et al., 2018a; Kim et al., 2017) . A case of asymptomatic tacrolimus-associated 16 thrombotic microangiopathy, diagnosed via laboratory tests, was reportedly treated with a 17 discontinuation of tacrolimus and administration of anticoagulant (Kim et al., 2018b) . Long-18 term immunosuppression with the mentioned above immunosuppressive regimens have 19 neither significantly affected white blood cell counts, liver enzyme levels, blood urea 20 nitrogen/creatinine levels, and hematocrit nor caused electrolyte imbalance in rhesus 21 recipients (Choi et al., 2018) . For the long-term survival of other xenografts including heart, kidney, and islet cells, 23 treatment with costimulation blockade agents is also crucial for maintenance therapy in most 24 pig-to-NHP transplantation experiments (Chan and Mohiuddin, 2017; Cooper et al., 2018; 25 Higginbotham et al., 2015; Liu et al., 2017; Wijkstrom et al., 2017) . Only two studies showed 26 long-term survival of neonatal or embryonic islet xenotransplants with CD40/CD154 27 pathway-sparing regimens using rituximab, anti-thymocyte globulin (ATG), and belatacept as 28 20 induction regimens; and abatacept, everolimus, and FTY720 as maintenance therapy (Hecht 1 et al., 2009; Thompson et al., 2012) . Corneal xenotransplant survival depends on the graft type, graft size, level of 6 immunosuppression, and a hierarchical discordance between the donor and the recipient 7 (Kim, 2017) . Therefore, the survival of corneal xenotransplants in NHP studies differs 8 between small and medium animal models. Given that porcine corneal matrix proteins 9 showed higher suitability for humans compared to other studied species (Sharifi et al., 2019) , the preclinical efficacy data of corneal xenotransplantation using pig donor are reviewed 11 (Table 9 ). The International Xenotransplantation Association (IXA) reached a consensus to set a 13 threshold for the preclinical efficacy of NHP study sufficient to justify starting a clinical trial for 14 corneal xenotransplantation (Kim et al., 2014) . NHP data support a clinical trial if the porcine 15 corneal xenotransplants survived for more than 6 months in five of eight consecutive NHPs; and ideally for 12 months in one or two successful cases (Kim et al., 2014 Since endothelial cells are not included, the immune response in ALK is less than in PKP. When the anterior lamellar (100 µm to anterior half thickness) grafts with a small diameter 22 (5.0 ∼7.0 mm) are transplanted, about 90 to 180 days of survival had been reported even 23 without immunosuppression (Amano et al., 2003; Li et al., 2011; Zhiqiang et al., 2007) . Meanwhile, although topical CS was used, thicker lamellar grafts (350∼400 µm) were 25 rejected within 21 days (Vabres et al., 2014 PKP requires strong immunosuppressants to overcome xenogeneic rejection. Since 7 corneal grafts of 7.5 to 8.0 mm size are commonly used in humans (Seitz et al., 2003) , the 8 outcome of NHP studies that used 7.5 mm or larger grafts is closer to the outcome of human 9 PKP than those with smaller grafts. Five studies have reported graft survival for more than 6 months (Choi et al., 2015; Kim et 11 al., 2018a; Yoon et al., 2020; Yoon et al., 2019; Zhiqiang et al., 2007) . Among these studies, 12 one satisfied the threshold requirements for a clinical trial with anti-CD40 Ab-or anti-CD20 Ab/tacrolimus-based immunosuppressive regimen (Table 9 ) (Kim et al., 2018a) . Conversely, 14 studies where CS and tacrolimus were applied failed to achieve long-term graft survival and 15 to reduce inflammatory biomarkers (Table 9 and 25 (Choi et al., 2015; Kim et al., 2018a; Yoon et al., 2019) . Regarding the GE porcine corneas, most PKP studies used various pigs including GT-KO. To date, GE porcine cornea did not show a significant increase in graft survival compared to 28 22 WT porcine cornea (Dong et al., 2017; Yoon et al., 2020) . Indeed, one study achieved long-1 term graft survival of GT-KO based GE porcine corneas, only when the recipients received 2 anti-CD20 Ab/tacrolimus-based immunosuppressive regimen (Yoon et al., 2020) . Furthermore, survival analysis showed no differences between WT and GE porcine cornea 4 regardless of steroid/tacrolimus-or anti-CD20 Ab-based regimens ( Fig. 7 ) (Yoon et al., 2020; 5 Yoon et al., 2019) . In GT-KO/CD46 transgenic porcine corneal grafts, T cell infiltration is 6 accompanied by an increased non-αGal Abs in NHPs (Dong et al., 2017) . Moreover, T and 7 B cells still infiltrate in hCTLA4-Ig transgenic porcine corneal grafts (Vabres et al., 2014) . This indicates that T and B cell-mediated reactions are not exempted in GE pigs that had 9 been available until now. Therefore, it remains unclear whether the absence of αGal 10 expression on GE porcine cornea might have an advantage over WT porcine cornea. . However, the graft size was too small (6.0 24 mm) to apply in human . EK with porcine corneal graft may be beneficial to 25 overcome xenogeneic rejection. Therefore, further studies of EK are required using a large 26 size of porcine graft to verify preclinical efficacy in NHPs. In summary, pig-to-NHP full-thickness corneal transplantation shows preclinical efficacy 1 with a clinically applicable graft size under co-stimulation blockade agents or anti-CD20 Abs/ 2 calcineurin inhibitor (CNI) combined regimen, while preclinical efficacy of pig-to-NHP ALK or 3 DSAEK has not been proved sufficient so far. Decellularization is a process to remove cells from tissues that will be used in cell-free 10 scaffolds. Since cellular components of the porcine cornea are the main source of the 11 xenoantigens (Lee et al., 2014c) , decellularized cornea has the advantage of reducing the 12 immune response after transplantation (Hargrave et al., 2003) . Although DPC is regarded as transplantation study using those grafts (Ju et al., 2012; Yoeruek et al., 2012a) . DPCs as anterior lamellar graft show long-term graft survival not only in NHP models but 25 also in human studies (Choi et al., 2011b; Zhang et al., 2015; Zheng et al., 2019) . Therefore, Chemical decellularization applies detergents including sodium dodecyl sulfate (SDS), 5 sodium deoxycholate, Triton X-100, peracetic acid, formic acid, ammonium hydroxide, 6 sodium chloride, and ethylenediaminetetraacetic acid (EDTA). Physical decellularization 7 includes agitation, freeze-thawing, electrophoresis, high hydrostatic pressure, osmotic 8 pressure, supercritical CO 2 , ultrasound, glycerol, and lyophilization (Li et al., 2017b) . Biological methods are mostly enzymes that include trypsin, dispase, phospholipase A 2 , 10 human serum, and nucleases. The ideal decellularization aims to remove all cellular components while maintaining the 12 transparency of the cornea and the structure of extracellular matrices (Isidan et al., 2019) . The following methods have been reported to be sufficient for the decellularization process: (1) 1.5 M NaCl alone or 0.05% trypsin/0.02% EDTA application after 1.5 M NaCl (Lee et al., and (7) Glycerol followed by chemical crosslinking (Lin et al., 2017) . were shown in DPC-grafted NHPs (Choi et al., 2011b) . Although αGal was not completely 26 removed, DPCs showed long-term survival in NHP studies compared to NPC grafts (Choi et 27 al., 2011b; Lee et al., 2014c) , suggesting that reduction of antigen load is beneficial. Since 28 chemicals are used for decellularization making cytotoxicity an issue, thorough washout 1 processes should be included in the decellularization procedures. Several studies show that 2 extracts of DPCs have no significant cytotoxicity when mixed with human or rabbit corneal 3 stromal cells Li et al., 2017b) and L929 cells (Zhou et al., 2011) or when 4 injected intravenously in mice . Transparency should be kept after decellularization. The transparency of DPC may vary 6 depending on the decellularization method, and DPCs through certain methods are not 7 satisfactory for clinical use (Lee et al., 2014c; Oh et al., 2009d; Riau et al., 2020) . Maintaining transparency have been reported in the following methods: N 2 , SDS, 9 hyper/hypotonic solution, hydrostatic pressure/DNase, freezing, hypertonic NaCl, freeze-10 thaw followed by incubation with DNase/RNase, or distilled water/trypsin/freeze-11 thaw/NaOH/DNase/RNase (Hashimoto et al., 2010; Lee et al., 2014c; Li et al., 2017b; Lin et 12 al., 2008; Luo et al., 2013; Oh et al., 2009d) . Dehydration with glycerol is widely used to re-13 gain transparency after decellularization (Hashimoto et al., 2010; Riau et al., 2020) . DPC The efficacy and histology of lamellar keratoplasties using DPCs are shown in Table 11 . Out of 22 studies that used rabbits or NHPs as recipients, 16 studies reported graft survival 25 more than 6 months (24 weeks). Among these 16 studies, in 2 studies long-term survival of 26 the DPC grafts was achieved even without the use of CSs (Oh et al., 2009d; Zhang et al., 27 2007) . In NHP studies, longer than 6-month survivals was shown in 14 recipients out of 15 28 (Choi et al., 2011b; Li et al., 2011) . Histological results showed that most DPC grafts had no 1 or mild inflammatory cell infiltration depending on the decellularization method. Therefore, 2 preclinical efficacy using DPC is proven in keratoplasty. Graft survival seems to be affected not only by cytotoxicity and antigenicity after the (Zhang et al., 2015) . In the second clinical trial, improvement of visual acuity was also reported in 9 out of 13 eyes 6 with herpes keratitis but graft melting was found in 3 eyes (Zheng et al., 2019) . In the third 7 clinical trial, 39 patients with progressive infectious keratitis underwent ALK using DPC for a 8 12 month-follow up. Twelve patients (30.8%) showed graft failure associated with herpetic 9 keratitis and a graft size larger than 8.0 mm Li et al., 2019) . In a case report, DPC tissue was transplanted in a patient with a corneal ulcer and histology showed minimal 11 infiltration of the inflammatory cells and migration of recipient's stromal cells. This suggests 12 that DPC may be biocompatible scaffold (Shi et al., 2017) . Although not registered as a clinical trial, two DPC clinical studies have also been reported The melting of DPC was more frequent in clinical studies than in the preclinical rabbit or 1 NHP studies. It is presumed by that 1) different hierarchical discordance may affect different 2 host immune responses (Wen et al., 2014) , 2) human corneal endothelial cells, unlike 3 rabbits, have limited mitotic capacity in vivo (Joyce, 2003; Van Horn et al., 1977) , 3) residual 4 donor cells or necrotic debris due to insufficient or toxic decellularization may have acted as 5 inflammatory inducers , and 4) unlike preclinical animal model with normal 6 cornea, the patients had diseases such as infectious keratitis, corneal perforation, or 7 autoimmune disease. Uncontrolled infections also cause melting of the grafts by releasing 8 matrix metalloproteinase from the recipient corneal cells. Taken together, whether DPC 9 would be biocompatible as a lamellar graft for diseased corneas is still controversial. Hence, further clinical study data related to DPC transplantation is required. To confirm the absence of nucleus, variable methods are suggested that include H&E or 4′, 4 6-diamidino-2-phenylindole (DAPI) staining, quantifying dsDNA, and identifying the 5 maximum length of DNA remnants (Fernandez-Perez and Ahearne, 2020). Evidence emerged that LKP using DPC is effective. For clinical application in humans, not 7 only standard manufacturing procedures of DPC but also standard procedures to verify 8 complete decellularization should be developed in order to be appropriately regulated by the 9 relevant laws as a medical device. The term 'xenosis', 'direct zoonosis', and 'xenozoonosis' is used to reflect the epidemiology 25 of infection transmitted from xenogeneic grafts (Fishman, 2018 (Fishman, , 2019 Fishman et al., 2012) . Corneal xenotransplantation procedure does not exempt the risk of transmission of 27 30 pathogens from animals to the recipients and the public. The challenges are the paucity of 1 data on the microbiology of pigs, which can cause xenozoonosis in humans, and the 2 absence of standardized screening and monitoring modalities for potential pathogens. because of immunosuppression. In particular, PERVs are a key concern since PERVs are 8 capable of infecting human cells in vitro (Patience et al., 1997) and PERV-A receptors have 9 been identified in various human tissues (Ericsson et al., 2003) . The major concern about 10 retroviral transmission is associated with altered gene regulation, oncogenesis, or DNA 11 recombination in the recipient by unapparent infection (Fishman et al., 2012) . PERV is present in the genome of all swine. PERV-A and -B can infect human and porcine 13 cells, while PERV-C only infects porcine cells (Scobie and Takeuchi, 2009) . The presence of 14 PERV-A/C recombinants is of special concern because they demonstrate high replication 15 efficacy and can be transmitted in human cells (Denner, 2008) . PERV expression is different 16 depending on the pig strain, the individual pig of a given strain, and different organs 17 (Bittmann et al., 2012; Tacke et al., 2003) . To date, PERV is found in all tested porcine 18 organs (Nellore, 2018) and the cornea Li et al., 2017a) . Experiences with pig-to-NHP transplantation provide insights into the potential risk of 22 xenozoonosis. There is no evidence for PERV transmission to NHP recipients from various 23 transplanted porcine cells, tissues, and organs (Garkavenko et al., 2008; Issa et al., 2008; 24 Loss et al., 2001; Martin et al., 1998; Switzer et al., 2001) . Regarding the cornea, transmission of PERV was not evident in both in vitro and in vivo corneal 26 transplantation studies Li et al., 2017a) . However, PERV was not 27 detectable up to 3.2 years post-PKP (Table 13 ) . Since the main receptor 28 31 for PERV entry, PERV-A receptor 1, is dysfunctional in NHPs (Denner et al., 2018) and NHP 1 cells are not permissive to replication by PERV (Ritzhaupt et al., 2002) , human studies are 2 essential to verify the actual potential of transmission of PERV. Early clinical studies using fetal neuronal cells (Dinsmore et al., 2000) , islet cells (Heneine et 12 al., 1998; Paradis et al., 1999) , or encapsulated islet cells (Elliott et al., 2000) also showed 13 no evidence of PERV infection for up to 7 years (Heneine et al., 1998) . Porcine cytomegalovirus (PCMV) can be excluded from pig colonies but is easily 25 reintroduced into herds (Clark et al., 2003) . Once established, PCMV infection is restricted to 26 xenotransplant causing consumptive coagulopathy and early renal graft loss in pig-to-NHP 27 transplantation Yamada et al., 2014) , however, it appears to be 28 32 resistant to ganciclovir . Porcine lymphotropic herpes virus (PLHV)-1 1 has a homology to EBV. Most of the porcine herds are positive for PLHV and is difficult to be 2 eliminated (Mueller et al., 2005) . Neither PLHV reactivation nor PTLD-like disease has been 3 reported in pig-to-NHP xenotransplantation with potent immunosuppression (Nellore, 2018) . Hepatitis E virus (HEV) is highly prevalent in pigs. HEV genotypes 3 and 4 infect both pig 5 and human causing neurological disorders or hepatitis (Nellore, 2018) . Porcine circovirus 6 (PCV) type 2 is considered an important pathogen of the immunosuppressed pig but not for 7 NHP and human recipients (Richmond et al., 2015) . Regarding coronaviruses ( (Sohrabi et al., 2020; Zhu et al., 2020) , which has 4 caused hundreds of thousands of deaths worldwide and brought the world to an economic 5 standstill, is a good example of such concern. This might justify public refusal of 6 xenotransplantation. Therefore, investigators should make every effort to minimize In particular, to prevent PERV infection, the following strategies are suggested: 1) careful 12 screening of the source pig herd, 2) selection of pigs that exhibit low-level expressions of 18 reduce the potential of PERV infection (Niu et al., 2017; Yang et al., 2015) . Taken together, we can infer that the actual risk of PERV transmission may be low in future clinical trials. To conduct xenotransplantation safely in clinical settings, the establishment of a regulatory 10 framework has been of special concern worldwide. In 1997, the US FDA placed ongoing 11 trials using porcine xenoproducts on hold until the development of appropriate PERV 12 detection methods and implementation of detection methods in the participant monitoring 13 (Bloom, 2001 (Bloom, , 2003 The WHO regulation was followed by a statement from the xenotransplantation advisory 14 Transparency includes full publication of data, independent experts' advice, and timely 15 independent data review (Noel, 2012 In line with global consensus mentioned above, required conditions for undertaking 22 xenotransplantation clinical trials were suggested for the porcine heart , islet Hering et al., 2016) , and cornea (Kim et al., 2014; Kim et al., 2013b) 24 products. The overall process of upcoming xenotransplantation clinical trials will adhere to ARMBA 13 are two standards applicable to these xenogeneic products (TGA, 2011 (TGA, , 2017 . The TGA at Department of Health has adopted the "Guideline on Xenogeneic Cell-based Medicinal (Appel et al., 2000) . Debates on self-identity was stimulated by the 'Baby Fae' case in 2 which a baboon heart was transplanted into a neonate (Bailey et al., 1985) . Nevertheless, self-identity is not generally compromised by xenotransplantation as a 4 current view of allograft considered as purely a functioning organ without affecting the 5 recipient's identity. Actually, it has been reported that although some participants for porcine proportion of opposition seems to be lower as time went on. The supporters of 10 xenotransplantation tend to be male and have higher formal education (Hagelin, 2004) . The results of attitude surveys on xenotransplantation from different specific cohort groups 12 are shown in Supplementary Given public concerns about pandemic COVID-19 this year, public attitude towards 5 xenotransplantation may have changed. Therefore, further studies should be mandatory to 6 investigate public acceptance on xenotransplantation. Case reports of xenotransplantation had been anecdotally published using NHP organs 25 (Bailey et al., 1985; Lambrigts et al., 1998; Michel et al., 2015; Starzl et al., 1993) . Given the 26 major drawbacks in using NHP donor organs (see chapter 2-1), NHP-to-human 27 xenotransplantation is no longer conducted. Cellular xenotransplantation using porcine or 28 rabbit islet cells has been performed in Russia, Ukraine, China, Mexico, New Zealand, and 1 Sweden. However, in most of these studies, no proper regulatory oversight was ensured 2 (Benikova et al., 1987; Danilova et al., 1989; Elliott et al., 2007; Groth et al., 1994 The following items are required for xenotransplant products stored or processed: (i) 14 All procedures must be recorded, including enucleation-to-preservation time, gross 15 examination of the cornea, findings of the slit-lamp examination, endothelial evaluation by a 16 specular microscope, and culture report (Choi et al., 2019b) . Porcine eyeball is harvested in the animal surgery room that maintains positive laminar flow 18 with regular temperature monitoring (20-26ºC), humidity (30-70%), and air quality (settle 19 plates (90 mm diameter) < 30 CFU/30 min)). The corneoscleral button is excised from the 20 eyeball and preserved in the biosafety cabinet (Class II, Type A2) that is in the GMP certified 21 cleanroom (Grade B). The biological property of porcine corneal xenotransplant is well maintained using the 23 same preservation protocol of human allograft . Based on CED changes 24 depending on age, the age of WT SNU miniature pig is limited to less than 72 month-old for 25 a suitable product . The remaining ocular tissues after harvest of the 26 cornea must be cultured to exclude contamination with mycoplasma, bacteria, and fungi, 27 and should be stored for a certain period of time (Kim et al., 2014) . The test outcome is 28 retrospectively available; therefore, action must be pre-planned in case the microbiologic 1 tests come back positive. Participants must be enrolled after full assessment of risks and benefits of corneal 5 xenotransplantation based on the international consensus statement (Kim et al., 2014) . The 6 clinical protocol for corneal xenotransplantation received the approval from the IRB in Korea 7 (Choi et al., 2019b) and was modified by the IXA and the Transplantation Society ethics 8 committee to ensure its safety and transparency after the field inspection . The latest revised inclusion and exclusion criteria of subjects for a clinical trial in corneal 10 xenotransplantation are shown in Table 15 . All the process will be conducted under the surveillance of the multidisciplinary consulting 19 boards to ensure the safety of the participants (Fig. 10) . Given the proof-of-concept NHP 20 study that included anti-CD20 Ab, tacrolimus, and CS (Choi et al., 2019a) , similar 21 immunosuppressant regimen will be adopted in a clinical trial (Choi et al., 2019b) . The MFDS will inspect the IRB-approved protocol and the qualities of xenotransplant products. Data and Safety Monitoring Board (DSMB) is independently organized, and will evaluate the 7 safety, monitor the overall process of the trial and advise to continue/discontinue or modify 8 the trial. The principal investigator should respond promptly to any suggestions of the DSMB 9 (Choi et al., 2019a; Choi et al., 2019b) . During clinical trials, the results will be periodically 10 submitted to the IRB and DSMB. The CDC is responsible for the prevention of xenozoonosis. If xenozoonosis is suspected, the event should be reported to the CDC. Detailed activities and surveillance programs in the protocol are as follows. Each participant 13 and his/her family members will be informed using IRB-approved consent forms. There will 14 be two separate deliberation time between signing two informed consent documents (before 15 and after screening tests). If necessary, other neutral advocate ophthalmologists will explain 16 the study in detail again (Table 16 ) (Choi et al., 2019b) . Regarding infection prophylaxis, the patients will receive prophylactic medication for 18 opportunistic infections based on blood test outcomes (Table 17) . Adverse reactions and 19 opportunistic infections will be closely monitored by regular blood tests and physical 20 examination (Table 18 ). The participant will be evaluated by a neuropsychiatrist for mental 21 competence of understanding informed consent. The first interview will evaluate (i) cognitive 22 ability, (ii) emotional competency, and (iii) psychopathological state at 12 weeks prior to 23 surgery. The second interview will evaluate (i) the understanding of xenotransplantation, and (ii) the understanding of the side effects of xenotransplantation 6 weeks prior to the surgery 25 (Table 19 ). If the score remains below a designated level, the subjects will be excluded from Through the pre-IND meetings, lot release criteria of corneal xenotransplant product will be 4 established that include (1) tests for purity, potency, and identity, (2) sterility test, (3) In xenotransplantation, safety is a critical concern for both individual participants and the However, as with the regulatory framework for safe implementation of xenotransplantation, public engagement is essential with education for potential benefits and risks of 1 xenotransplantation, and the participation of the decision-making procedures. With accumulating evidence and recent achievements for preclinical efficacy, corneal However, it is still controversial whether corneal xenotransplantation can be a clinically 19 relevant option to replace allotransplantation. The COVID-19 pandemic hugely impacts both 20 public and personal lives and brings us to a worldwide economic crisis (Adam, 2020) . Given 21 that COVID-19 is also suspected as a zoonotic infection with presumably bat origin (Lau et cost to maintain DPF pig or to produce GE pigs as well as the costly process to provide 27 corneal xenoproduct may be regarded as a practical concern to distribute corneal 28 54 xenoproduct in developing countries where xenotransplantation may actually be required. Finally, many countries still do not have a regulatory framework for corneal 2 xenotransplantation that should be set before a clinical implementation. These issues should 3 be addressed and attempted to be solved in collaboration with the ophthalmologic and 4 xenotransplantation society. Although the preclinical efficacy using DPC is proven in keratoplasty, the legal definition of NHPs with wild-type porcine corneal grafts with different immunosuppressive regimens. All 2 grafts were rejected in the steroid group within 4 weeks, while long-term graft survival (>6 3 months) was shown in anti-CD154 Ab (aCD154), anti-CD40 Ab (aCD40), and anti-CD20 Ab 4 (aCD20) groups. Rejected grafts show densely infiltrated by CD3 + CD4 + T, CD3 + CD8 + T, and 5 CD3 -CD20 + B cells and CD68 + macrophages with dense depositions of IgG and C3c. Note: Fluorescein color of CD8 and CD20 are green in Steroid and aCD154 groups, and red 11 in aCD40 and aCD20 groups. All NHPs received methylprednisolone intramuscularly at an initial dose of 2 mg/kg/d and 13 tapered over 5 weeks. Costimulation blockade (CoB) group than in steroid (S) or steroid + tacrolimus (S+T) group 4 (log-rank test, P < 0.05), while no differences of MST were found between S and S+T group 5 or between aCD20 and CoB group, respectively. (G) The postoperative level of C3a in the 6 aqueous humor was significantly higher in S group than in aCD20 or CoB group, (H) level of 7 donor-specific IgG was significantly higher in S group than in the aCD20 or CoB group as (Hara and Cooper, 2011; Kissam, 1844 Kissam, ) 1905 Rabbit Kidney slice 16 days Princeteau (Lambrigts et al., 1998; Princeteau, 1905 Princeteau, ) 1906 Pig Kidney 3 days Mathieu Jaboulay (Jaboulay, 1906; Lambrigts et al., 1998 Lambrigts et al., ) 1963 Lambrigts et al., -1964 Chimpanzee Kidneys Up to 9 months Keith Reemtsma (Michel et al., 2015; Reemtsma et al., 1964 Reemtsma et al., ) 1964 Gibbon Cornea > 5 months † Soomsawasdi B (Soomsawasdi et al., 1964 Chimpanzee Heart 2 hours James Hardy (Hardy et al., 1964; Michel et al., 2015 Michel et al., ) 1984 Baboon Heart 20 days Leonard Bailey (Bailey et al., 1985; Michel et al., 2015 Michel et al., ) 1992 Baboon Livers 70 days Thomas Starzl (Starzl et al., 1993 (Starzl et al., ) 2013 (Starzl et al., -2017 New born pig Islets NA (Elsheikh et al., 2008) 5 * α is scale factor and β is the exponent of the nonlinear relationship between stress and strain using the strip 6 extensiometry method (Zeng et al., 2001) . 7 ** P(X100) is the value of G(t) at the end of the stress-relaxation test, K is the slope of fitted G(t)-ln t line, and both 8 data were statistically significant between pig and human (Zeng et al., 2001) . 9 *** Average loss of initial stress after 400s in Stress-relaxation behavior (Elsheikh et al., 2008) 10 The ratio of average creep strain at 300 and 1000 s between pig and human showed statistical significance 11 (Elsheikh et al., 2008) 12 † the swelling pressure in the full-thickness porcine corneas at 0% compression, at 760 μm (Sondergaard et al., 13 2013b) 14 ‡ the swelling pressure at a standard stromal thickness of 500 μm (Han et al., 2015; Olsen and Sperling, 1987) 15 † † In vivo human data with non-contact specular microscopy (Snellingen et al., 2001) 16 Significantly shortened survival compared with that of control (9.4 D)* or with that of anti CD4 Ab treated group (44.1 D)** Significantly shortened survival compared with that of SCID reconstituted with CD4 + /CD8 + T cell-depleted splenocytes (49 D) *** and increased survival compared with that of SCID reconstituted with whole splenocytes (15 D)*** Table 8 . Xenogeneic rejection mechanism of orthotopic corneal xenotransplantation in pig-to-small or medium sized animal model. Abbreviations: Ab: antibody, αGal: Galα1-3Galβ1-4GlcNAc-R, AH: aqueous humor, ALK: anterior lamellar keratoplasty, BMT: bone marrow transplantation, C3c & C3a: component of complement fragment, CD: cluster of differentiation, CMAH: cytidine monophospho-N-acetylneuraminic acid hydroxylase, DALK: deep anterior lamellar keratoplasty, DSAEK: Descemet stripping automated endothelial keratoplasty, FT: fucosyltransferase, GE: genetically-engineered, GT: α1,3-galactosyltransferase, GT-KO: α1,3-galactosyltransferase gene-knockout, hCTLA4-Ig: human cytotoxic T-lymphocyte associated antigen 4-immunoglobulin, hCD39: human ectonucleoside triphosphate diphosphohydrolase-1, hCD46: human complementary regulatory protein, hCD55: human complement decay-accelerating factor, hCD59: human MAC-inhibitory protein, iGb3s: isoglobotrihexosylceramide 3 synthase, IVIG: intravenous immunoglobulin, IFNγ : interferon gamma, IL: interleukin, IP-10: interferon gamma-induced protein, PKP: penetrating keratoplasty, MCP: monocyte chemoattractant protein, M: months, RANTES: regulated upon activation normal T cell expressed and secreted, SNU: Seoul National University, TNFα: tumor necrosis factor-α, W: weeks, WZS: Wuzhishan, WT: wild-type Tacrolimus was intramuscularly administered twice daily at a dose of 0.05 a or 0.035 c mg/kg or at a dose of 0.05 mg/kg for 4 weeks followed by 0.035 mg/kg e . Anti-CD20 Ab was intravenously administered at a dose of 20 mg/kg on postoperative days 0 and 7, and every 2 b or 3 d months. *Posterior lamellar graft was made after removal of anterior lamellae by 510 ㎛. † One corneal graft that survived 165 days was derived from a pig of the crossbreeding Landrace with Chicago minipig. * Immunosuppressive drugs used in successful combinations that enabled long-term survival of porcine xenotransplants (more than 6 months) in non-human primate recipients. *Studies using tissue engineered decellularized porcine cornea are not included in this table. †Some recipients were sacrificed at specific time points for histologic examinations. ‡ Sacrificed for histology • Pregnant women, wish to fall pregnant in the future, breast-feeding a baby • A mentally ill incapacitated or a non-compliance • Chronic alcoholism, Cardiac disease, CVA, Liver disease, History of malignancy, COPD • Hypersensitivity to medication which will be used after transplantation Abbreviations: COPD: chronic obstructive pulmonary disease, CVA: cerebrovascular accident *Legal blindness is defined by American Medical Association and the United States Congress Fc receptor Control all health-related issues Level of acceptance of islet cell and kidney xenotransplants by personnel of hospitals with and without experience in clinical xenotransplantation Deciphering the EU clinical trials regulation Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation Special report: The simulations driving the world's response to COVID-19 An indentation technique to characterize the mechanical and viscoelastic properties of human and porcine corneas A 15-Year Review of Corneal Transplant in Brazil Antigenicity of porcine cornea as xenograft Decellularizing corneal stroma using N2 gas Xenotransplantation: a bioethical evaluation Xenotransplantation: the challenge to current psychosocial attitudes Penetrating Keratoplasty at a Experimental research with corneal heterografts Baboon-tohuman cardiac xenotransplantation in a neonate Respect for persons, informed consent and the assessment of infectious disease risks in xenotransplantation Topical cyclosporine in highrisk corneal transplants Experience with the treatment of children with diabetes mellitus using allo-and xenografts of cultures of pancreatic islet cells Corneal transplantation trends in France from 2004 to 2015: A 12-year review An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty Expression of porcine endogenous retroviruses (PERV) in different organs of a pig Xenotransplantation: regulatory challenges Xenotransplantation--federal regulatory considerations The current state of stem cell therapy for ocular disease Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation Differential expression of the complement regulatory proteins in the human eye Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis Alternatives to eye bank native tissue for corneal stromal replacement Does human leukocyte antigens sensitization matter for xenotransplantation? Xenotransplantation 25 Cell Therapy in Solid Organ Transplantation Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways Bioengineered corneas: how close are we? Corneal cell therapy: with iPSCs, it is no more a far-sight Quantitative determinations of complement components and immunoglobulins in tears and aqueous humor Immunosuppression following heart transplantation: prospects and challenges Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation Islet Xeno/transplantation and the risk of contagion: local responses from Canada and Australia to an emerging global technoscience Standardization of the proceedings for preparing clinical trials of corneal xenotransplantation in South Korea Longterm safety from transmission of porcine endogenous retrovirus after pig-to-non-human primate corneal transplantation Effect of alphaGal on corneal xenotransplantation in a mouse model Efficacy of pig-to-rhesus lamellar corneal xenotransplantation Blockade of CD40-CD154 costimulatory pathway promotes long-term survival of full-thickness porcine corneal grafts in nonhuman primates: clinically applicable xenocorneal transplantation Protocol for the first clinical trial to investigate safety and efficacy of corneal xenotransplantation in patients with corneal opacity, corneal perforation, or impending corneal perforation Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation Role of natural killer cells in the rejection process of corneal allografts in rats Porcine cytomegalovirus in pigs being bred for xenograft organs: progress towards control Distribution of non-gal antigens in pig cornea: relevance to corneal xenotransplantation Clinical xenotransplantion--how close are we? Will the pig solve the transplantation backlog? Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present 94 status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases Progress in Clinical Encapsulated Islet Xenotransplantation Progress in pig-to-non-human primate transplantation models (1998-2013): a comprehensive review of the literature Xenotransplantation-the current status and prospects Long-term outcomes and management of lung transplant recipients Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs Effect of the transplantation of cultured pancreatic islet cell on the status of diabetic microangiopathy Extrait d'une Lettre de M.Denis, professeur de philosophie et de mathématique à M… touchant la transfusion du sang Recombinant porcine endogenous retroviruses (PERV-A/C): a new risk for xenotransplantation? Is it currently possible to evaluate the risk posed by PERVs for clinical xenotransplantation? First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 5: recipient monitoring and response plan for preventing disease transmission Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty Management of Immunosuppression in Liver Transplantation PHS guideline on infectious disease issues in xenotransplantation Informed Consent in Clinical Research Involving Xenotransplantation Management of high-risk corneal transplantation No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells Initial study of alpha1,3-galactosyltransferase gene-knockout/CD46 pig full-thickness corneal xenografts in rhesus monkeys Emergency Keratoplasty with Porcine Xenografts in Necrotizing Keratitis Development and characterization of a full-thickness acellular porcine cornea matrix for tissue engineering Histological evaluation and biomechanical characterisation of an acellular porcine cornea scaffold Medical Standards of the Eye Bank Association of America (EBAA) Xenotransplantation 2.0 Guide to the quality and safety of tissues and cells for human application Clinical xenotransplantation: the next medical revolution? Xenotransplantation: past, present, and future No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation Biomechanical properties of human and porcine corneas Guideline on Xenogeneic Cell-based Medicinal Products Guideline on quality, non-clinical and clinical aspects of 4 medicinal products containing genetically modified cells Identification of receptors for pig endogenous retrovirus Orthotopic porcine corneal xenotransplantation using a human graft Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival FDA, 2016a. 21st Century Cures Act Medical Devices Containing Materials Derived from Animal Sources (Except for Guidance for Industry and Food and Drug Administration Staff Source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry CVM GFI #187 regulation of intentionally altered genomic DNA in animals Decellularization and recellularization of cornea: Progress towards a donor alternative Infection in Organ Transplantation Infectious disease risks in xenotransplantation Infection in xenotransplantation: opportunities and challenges Xenotransplantation-associated infectious risk: a WHO consultation Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis Trends in Corneal Transplantation from 2001 to 2016 in Germany: A Report of the DOG-Section Cornea and its Keratoplasty Registry Cell-based therapies for ocular inflammation Comparison of proliferative capacity of genetically-engineered pig and human corneal endothelial cells Global Survey of Corneal Transplantation and Eye Banking Absence of transmission of potentially xenotic viruses in a prospective pig to primate islet xenotransplantation study Xenotransplantation: an ethical dilemma Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation Effects of Detergent-Based Protocols on Decellularization of Corneas With Sclerocorneal Limbus Generation of bioengineered corneas with decellularized xenografts and human keratocytes Regenerative approaches for the cornea Transplantation of porcine fetal pancreas to diabetic patients Public opinion surveys about xenotransplantation Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection Quantitative assessment of corneal viscoelasticity using optical coherence elastography and a modified Rayleigh-Lamb equation Fish cornea for grafting The immunology of corneal xenotransplantation: a review of the literature Xenotransplantation--the future of corneal transplantation? Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs Human dominant-negative class II transactivator transgenic pigs -effect on the human anti-pig T-cell immune response and immune status Heart Transplantation in Man. Developmental Studies and Report of a Case Are corneal cells susceptible to antibody-mediated killing in corneal allograft rejection? High-risk corneal allografts are capable of stimulating complement dependent cytolytic antibodies Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study Preparation and characterization of decellularized cornea using high-hydrostatic pressurization for corneal tissue engineering Corneal Regeneration by Deep Anterior Lamellar Keratoplasty (DALK) Using Decellularized Corneal Matrix Ultrastructural analysis of the decellularized cornea after interlamellar keratoplasty and microkeratome-assisted anterior lamellar keratoplasty in a rabbit model The 2018 Changsha Communique" The 10-Year Anniversary of The International Consultation on Xenotransplantation Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody Cutting and Decellularization of Multiple Corneal Stromal Lamellae for the Bioengineering of Endothelial Grafts Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts The use of basiliximab in solid organ transplantation The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--executive summary First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Executive summary Preventing T cell rejection of pig xenografts CD8+ T cell-mediated delayed rejection of orthotopic guinea pig cornea grafts in mice deficient in CD4+ T cells Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy Basics of biomechanics Susceptibility of corneal allografts and xenografts to antibody-mediated rejection Immune privilege in corneal transplantation Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation Preparation of acellular scaffold for corneal tissue engineering by supercritical carbon dioxide extraction technology Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty Committee on Xenograft Transplantation: Ethical Issues and Public Policy Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells Decellularization methods for developing porcine corneal xenografts and future perspectives Absence of replication of porcine endogenous retrovirus and porcine lymphotropic herpesvirus type 1 with prolonged pig cell microchimerism after pig-to-baboon xenotransplantation Greffe de reins au pli du coude par soudures arterielles et veineuses Survival of pig-to-rhesus corneal xenografts prolonged by prior donor bone marrow transplantation European eye bank association Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients Tacrolimus immunosuppression in high-risk corneal grafts Proliferative capacity of the corneal endothelium A human corneal endothelium equivalent constructed with acellular porcine corneal matrix The immunological indices of diabetic patients following the transplantation of a pancreatic islet cell culture Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand Biophysicofunctional compatibility of Seoul National University (SNU) miniature pig cornea as xenocorneal graft for the use of human clinical trial Presurgical corticosteroid treatment improves corneal transplant survival in mice Comparative efficacy of anti-CD40 antibody-mediated costimulation blockade on long-term survival of full-thickness porcine corneal grafts in nonhuman primates Anti-CD40 antibody-mediated costimulation blockade promotes long-term survival of deep-lamellar porcine corneal grafts in non-human primates Tacrolimus-induced asymptomatic thrombotic microangiopathy diagnosed by laboratory tests in pig-to-rhesus corneal xenotransplantation: A case report Commentary: Current Status and Future of Corneal Xenotransplantation Current Progress in corneal Xenotransplantation The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of xenocorneal transplantation Current status of corneal xenotransplantation Korean External Eye Disease, S., 2013b. Ethical and regulatory guidelines in clinical trials of xenocorneal transplantation in Korea; the Korean xenocorneal transplantation consensus statement Identification of alpha-Gal and non-Gal epitopes in pig corneal endothelial cells and keratocytes by using mass spectrometry Trends in immunosuppression after pancreas transplantation: what is in the pipeline? Porcine endogenous retroviruses in xenotransplantation--molecular aspects The role of CD154 in organ transplant rejection and acceptance Ceratoplastice in man Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning Discordant organ xenotransplantation in primates: world experience and current status Corneal blindness and xenotransplantation Consistent success in life-supporting porcine cardiac xenotransplantation The host response in experimental corneal xenotransplantation Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2 Trends and Determinants of Familial Consent for Corneal Donation in Chinese Gal expression of the cornea in vitro, in vivo and in xenotransplantation The role of cyclosporine and mycophenolate in an orthotopic porcine-to-rat corneal xenotransplantation The attitude toward xenocorneal transplantation in wait-listed subjects for corneal transplantation in Korea Xenotransplantation using lyophilized acellular porcine cornea with cells grown in vivo and stimulated with substance-p The effect of lyophilization on graft acceptance in experimental xenotransplantation using porcine cornea Characterization of porcine corneal endothelium for xenotransplantation Development of retrocorneal membrane following pig-to-monkey penetrating keratoplasty A comparison of three methods of decellularization of pig corneas to reduce immunogenicity Expression of NeuGc on Pig Corneas and Its Potential Significance in Pig Corneal Xenotransplantation Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus Comparison of immunogenicity and porcine-to-rhesus lamellar corneal xenografts survival between fresh preserved and dehydrated porcine corneas Corneal Xenotransplantation From Pig to Rhesus Monkey: No Signs of Transmission of Endogenous Porcine Retroviruses Preparation and Biomechanical Properties of an Acellular Porcine Corneal Stroma Healing characteristics of acellular porcine corneal stroma following therapeutic keratoplasty Risk factors influencing survival of acellular porcine corneal stroma in infectious keratitis: a prospective clinical study Xenotransplantation: role of natural immunity Immunosuppression for kidney transplantation: Where are we now and where are we going? Lamellar keratoplasty with a graft of lyophilized acellular porcine corneal stroma in the rabbit Cross-linked decellularized porcine corneal graft for treating fungal keratitis The feasibility and efficacy of preparing porcine Descemet's membrane endothelial keratoplasty (DMEK) grafts by two techniques: An ex-vivo investigation for future xeno-DMEK Porcine endothelial grafts could survive for a long term without using systemic immunosuppressors: An investigation of feasibility and efficacy of xeno-Descemet's stripping automated endothelial keratoplasty from WZS-pig to rhesus monkey Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future Analysis of potential porcine endogenous retrovirus (PERV) transmission in a whole-organ xenotransplantation model without interfering microchimerism Construction of tissueengineered cornea composed of amniotic epithelial cells and acellular porcine cornea for treating corneal alkali burn Regulation of corneal angiogenesis in limbal stem cell deficiency Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice A new edition of the Declaration of Istanbul: updated guidance to combat organ trafficking and transplant tourism worldwide Porcine endogenous retrovirus (PERV) was not transmitted from transplanted porcine endothelial cells to baboons in vivo Etiology of Global Corneal Blindness and Current Practices of Corneal Transplantation: A Focused Review Clinical porcine islet xenotransplantation under comprehensive regulation Current status and future of clinical islet xenotransplantation Changing Indications in Penetrating Keratoplasty: A Systematic Review of 34 Years of Global Reporting Corneal regeneration: A review of stromal replacements PERVading strategies and infectious risk for clinical xenotransplantation Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain The future of keratoplasty: cell-based therapy, regenerative medicine, bioengineering keratoplasty, gene therapy Current progress in xenotransplantation and organ bioengineering Alternate and classical pathway components of complement in the normal cornea No PERV transmission during a clinical trial of pig islet cell transplantation Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28 Ocular surface reconstruction using stem cell and tissue engineering Infections after xenotransplantation Immune mechanisms of corneal allograft rejection Immune privilege of corneal allografts Anterior chamber-associated immune deviation promotes corneal allograft survival CD4+ T-cell-independent rejection of corneal allografts Differential roles of CD8+ and CD8-T lymphocytes in corneal allograft rejection in 'high-risk' hosts Tissue engineering of the cornea Absence of PERV infection in baboons after transgenic porcine liver perfusion Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9 Global regulatory requirements for xenotransplantation clinical trials Tolerogenic dendritic cells in organ transplantation Acute cell-mediated rejection in orthotopic pig-to-mouse corneal xenotransplantation Histological differences in full-thickness vs. lamellar corneal pig-to-rabbit xenotransplantation Complement depletion with cobra venom factor delays acute cell-mediated rejection in pig-to-mouse corneal xenotransplantation Processing porcine cornea for biomedical applications Lamellar corneal pig-to-rabbit xenotransplantation The swelling pressure of the human corneal stroma as determined by a new method Coronavirus disease 2019 (COVID-19) outbreak: Could pigs be vectors for human infections? Chimerism-based tolerance in organ transplantation: preclinical and clinical studies A rabbit anterior cornea replacement derived from acellular porcine cornea matrix, epithelial cells and keratocytes Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group Current status of xenotransplantation in South Korea No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys Infection of human cells by an endogenous retrovirus of pigs Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye Finite element modeling of the viscoelastic responses of the eye during microvolumetric changes Xenotransplantation makes a comeback Review of Infectious Disease Prophylaxis in Solid Organ Transplantation Corneal ratto-mouse xenotransplantation and the effects of anti-CD4 or anti-CD8 treatment on cytokine and nitric oxide production Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system A Review of the Literature on the Global Epidemiology of Corneal Blindness Greffe renale Molecular mechanisms of immunity in corneal allotransplantation and xenotransplantation Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice Renal Heterotransplantation in Man Mesenchymal Stromal Cell Therapy for Solid Organ Transplantation Die keratoplastik, ein versuch zur enweiterund der augenheilkunde Stromal keratophakia: Corneal inlay implantation PD-L1 expression is increased in monocyte derived dendritic cells in response to porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus infections Characterization of the in vitro and in vivo properties of CFZ533, a blocking and nondepleting anti-CD40 monoclonal antibody Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines Therapeutic monoclonal antibodies in ophthalmology Past, Present, and Future of Regulatory T Characteristics of corneal xenograft rejection in a discordant species combination Histopathologic features of rejecting orthotopic corneal xenografts Transplantation tolerance through mixed chimerism: From allo to xeno In vivo evaluation of a novel scaffold for artificial corneas prepared by using ultrahigh hydrostatic pressure to decellularize porcine corneas The past, present, and future of costimulation blockade in organ transplantation NK cell depletion delays corneal allograft rejection in baby rats Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts Porcine endogenous retrovirus and other viruses in xenotransplantation FTY720 in corneal concordant xenotransplantation Impact of graft diameter on corneal power and the regularity of postkeratoplasty astigmatism before and after suture removal International human xenotransplantation inventory Experience in xenografts of pancreatic islet cell cultures after surgical treatment of chronic pancreatitis A novel method in preparation of acellularporcine corneal stroma tissue for lamellar keratoplasty Finding an Optimal Corneal Xenograft Using Comparative Analysis of Focus on the clinical application of the first artificial bioengineered cornea in China Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation Update regarding xenotransplantation in Japan The ethics debate in relation to xenotransplantation Quantitative and morphological characteristics of the human corneal endothelium in relation to age, gender, and ethnicity in cataract populations of South Asia An overview of the role of society and risk in xenotransplantation Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59 World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) Corneal resistance to shear force after UVA-riboflavin cross-linking Reduction of stromal swelling pressure after UVA-riboflavin cross-linking Heterokeratoplasty using gibbon donor cornea Clinical trials of xenotransplantation: waiver of the right to withdraw from a clinical trial should be required Xenotransplantation: where are we in 2008? Baboon-to-human liver transplantation Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul Regenerating Eye Tissues to Preserve and Restore Vision Ocular immune privilege: therapeutic opportunities from an experiment of nature Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas Neural control of ocular immune privilege Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs Position paper of the Ethics Committee of the International Xenotransplantation Association Differences in release and determination of subtype of porcine endogenous retroviruses produced by stimulated normal pig blood cells Corneal transplantation Acute rejection of orthotopic corneal xenografts in mice depends on CD4(+) T cells and self-antigen-presenting cells Xenoreactive CD4+ T cells and acute rejection of orthotopic guinea pig corneas in mice Psychosocial aspects of xenotransplantation: survey in adolescent recipients of porcine islet cells Therapeutic Goods Order No Therapeutic Goods (Manufacturing Principles) Determination The European Parliament and of the Council The European Parliament and of the Council The European Parliament and of the Council The Barcelona Principles: An Agreement on the Use of Human Donated Tissue for Ocular Transplantation, Research, and Future Technologies(c) Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival The Falun Gong, organ transplantation, the holocaust and ourselves Clinical efficacy of therapeutic keratoplasty using corneal xenografts in patients with corneal ulcers hCTLA4-Ig transgene expression in keratocytes modulates rejection of corneal xenografts in a pig to non-human primate anterior lamellar keratoplasty model No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study Clinical islet xenotransplantation: how close are we? Matching for Human Leukocyte Antigens (HLA) in corneal transplantation -to do or not to do Regenerative capacity of the corneal endothelium in rabbit and cat Avastin use in high risk corneal transplantation Biomechanical properties of the keratoconic cornea: a review Costimulation blockade with belatacept in renal transplantation Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study A pilot trial with pig-to-man islet transplantation at the 3rd Xiang-Ya Hospital of the Central South University in Changsha A clinical trial of xenotransplantation of neonatal pig islets for diabetic patients Xenotransplantation in China: Present status K-mer natural vector and its application to the phylogenetic analysis of genetic sequences WHO guidance on xenogeneic infection/disease surveillance and response: a strategy for international cooperation and coordination Fifty-seventh World Health Assembly Statement from the Xenotransplantation Advisory Consultation First WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials Second WHO global consultation on regulatory requirements for xenotransplantation clinical trials Renal xenotransplantation: experimental progress and clinical prospects Corneal blindness and current major treatment concern-graft scarcity The use of phospholipase A(2) to prepare acellular porcine corneal stroma as a tissue engineering scaffold Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154 Development of a rabbit corneal equivalent using an acellular corneal matrix of a porcine substrate Porcine cytomegalovirus infection is associated with early rejection of kidney grafts in a pig to baboon xenotransplantation model Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506 Bilateral Alterations in Corneal Nerves, Dendritic Cells, and Tear Cytokine Levels in Ocular Surface Disease Genome-wide inactivation of porcine endogenous retroviruses (PERVs) Decellularization of porcine corneas and repopulation with human corneal cells for tissue-engineered xenografts Reconstruction of corneal stroma with decellularized porcine xenografts in a rabbit model Long-term survival of full-thickness corneal xenografts from alpha1,3-galactosyltransferase gene-knockout miniature pigs in non-human primates Predictive biomarkers for graft rejection in pig-to-non-human primate corneal xenotransplantation Corneal donations in South Africa: A 15-year review A comparison of biomechanical properties between human and porcine cornea Survival and integration of tissue-engineered corneal stroma in a model of corneal ulcer Lamellar keratoplasty treatment of fungal corneal ulcers with acellular porcine corneal stroma Short-term results of acellular porcine corneal stroma keratoplasty for herpes simplex keratitis Porcine small intestine submucosa (SIS) is not an acellular collagenous matrix and contains porcine DNA: possible implications in human implantation An Experimental Study of Femto-Laser in Assisting Xenograft Acellular Cornea Matrix Lens Transplantation WZS-pig is a potential donor alternative in corneal xenotransplantation The complex functioning of the complement system in xenotransplantation Development and characterization of acellular porcine corneal matrix using sodium dodecylsulfate A Novel Coronavirus from Patients with Pneumonia in China Eine erfolgreiche totale Keratoplastik (A successful total keratoplasty) Development of decellularized porcine cornea and efficacy data Efficacy, safety, and histological studies in keratoplasty using decellularized Clinical trials in organ or cellular xenotransplantation 10.1.1. Current worldwide status of clinical trials in xenotransplantation 10.1.2. Requirements for investigational new drug submission for xenotransplant product 10.2. Process of clinical trials in corneal xenotransplantation 10.2.1. Quality control of source herds